Variant | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AF EXOME | AF GENOME | Disease | Disease Class | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.605 | 0.640 | 12 | 68808800 | intron variant | T/G | snv | 0.31 |
|
0.700 | 0 | |||||||||||
|
0.605 | 0.640 | 12 | 68808800 | intron variant | T/G | snv | 0.31 |
|
Neoplasms | 0.020 | < 0.001 | 2 | 2014 | 2016 | |||||||
|
0.605 | 0.640 | 12 | 68808800 | intron variant | T/G | snv | 0.31 |
|
Neoplasms | 0.020 | < 0.001 | 2 | 2014 | 2016 | |||||||
|
0.605 | 0.640 | 12 | 68808800 | intron variant | T/G | snv | 0.31 |
|
Neoplasms | 0.020 | < 0.001 | 2 | 2014 | 2016 | |||||||
|
0.925 | 0.080 | 12 | 68839568 | missense variant | A/G | snv | 7.0E-06 |
|
Neoplasms; Skin and Connective Tissue Diseases | 0.010 | < 0.001 | 1 | 2016 | 2016 | |||||||
|
0.925 | 0.080 | 12 | 68839568 | missense variant | A/G | snv | 7.0E-06 |
|
Neoplasms; Skin and Connective Tissue Diseases | 0.010 | < 0.001 | 1 | 2016 | 2016 | |||||||
|
0.550 | 0.720 | 12 | 68839311 | missense variant | C/G | snv | 4.0E-06 |
|
Neoplasms; Stomatognathic Diseases; Otorhinolaryngologic Diseases | 0.010 | < 0.001 | 1 | 2015 | 2015 | |||||||
|
0.550 | 0.720 | 12 | 68839311 | missense variant | C/G | snv | 4.0E-06 |
|
Hemic and Lymphatic Diseases | 0.010 | < 0.001 | 1 | 2012 | 2012 | |||||||
|
0.550 | 0.720 | 12 | 68839311 | missense variant | C/G | snv | 4.0E-06 |
|
Neoplasms; Male Urogenital Diseases | 0.010 | < 0.001 | 1 | 2010 | 2010 | |||||||
|
0.550 | 0.720 | 12 | 68839311 | missense variant | C/G | snv | 4.0E-06 |
|
Digestive System Diseases; Neoplasms | 0.010 | < 0.001 | 1 | 2014 | 2014 | |||||||
|
0.550 | 0.720 | 12 | 68839311 | missense variant | C/G | snv | 4.0E-06 |
|
Digestive System Diseases; Neoplasms | 0.010 | < 0.001 | 1 | 2014 | 2014 | |||||||
|
0.550 | 0.720 | 12 | 68839311 | missense variant | C/G | snv | 4.0E-06 |
|
Neoplasms; Immune System Diseases; Hemic and Lymphatic Diseases | 0.010 | < 0.001 | 1 | 2007 | 2007 | |||||||
|
0.550 | 0.720 | 12 | 68839311 | missense variant | C/G | snv | 4.0E-06 |
|
Neoplasms | 0.010 | < 0.001 | 1 | 2012 | 2012 | |||||||
|
0.925 | 0.080 | 12 | 68839466 | missense variant | A/G | snv | 4.0E-06 |
|
Neoplasms; Skin and Connective Tissue Diseases | 0.010 | < 0.001 | 1 | 2016 | 2016 | |||||||
|
0.925 | 0.080 | 12 | 68839466 | missense variant | A/G | snv | 4.0E-06 |
|
Neoplasms; Skin and Connective Tissue Diseases | 0.010 | < 0.001 | 1 | 2016 | 2016 | |||||||
|
0.925 | 0.080 | 12 | 68809257 | missense variant | A/G | snv | 4.0E-06 |
|
Neoplasms; Male Urogenital Diseases | 0.010 | < 0.001 | 1 | 2015 | 2015 | |||||||
|
0.925 | 0.080 | 12 | 68809257 | missense variant | A/G | snv | 4.0E-06 |
|
Neoplasms; Male Urogenital Diseases | 0.010 | < 0.001 | 1 | 2015 | 2015 | |||||||
|
12 | 68816914 | missense variant | G/C | snv | 4.0E-06 |
|
Neoplasms | 0.010 | < 0.001 | 1 | 2019 | 2019 | |||||||||
|
12 | 68816914 | missense variant | G/C | snv | 4.0E-06 |
|
Neoplasms | 0.010 | < 0.001 | 1 | 2019 | 2019 | |||||||||
|
12 | 68816914 | missense variant | G/C | snv | 4.0E-06 |
|
Neoplasms | 0.010 | < 0.001 | 1 | 2019 | 2019 | |||||||||
|
1.000 | 0.120 | 12 | 68839350 | missense variant | G/A | snv | 5.2E-05 | 2.1E-05 |
|
Neoplasms; Stomatognathic Diseases; Otorhinolaryngologic Diseases | 0.010 | < 0.001 | 1 | 2015 | 2015 | ||||||
|
0.550 | 0.720 | 12 | 68839311 | missense variant | C/G | snv | 4.0E-06 |
|
Neoplasms; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | 0.020 | 0.500 | 2 | 2007 | 2011 | |||||||
|
0.550 | 0.720 | 12 | 68839311 | missense variant | C/G | snv | 4.0E-06 |
|
Digestive System Diseases; Neoplasms | 0.020 | 0.500 | 2 | 2011 | 2015 | |||||||
|
0.550 | 0.720 | 12 | 68839311 | missense variant | C/G | snv | 4.0E-06 |
|
Hemic and Lymphatic Diseases | 0.020 | 0.500 | 2 | 2012 | 2015 | |||||||
|
0.550 | 0.720 | 12 | 68839311 | missense variant | C/G | snv | 4.0E-06 |
|
Digestive System Diseases; Neoplasms | 0.020 | 0.500 | 2 | 2010 | 2013 |